Introduction {#S0001}
============

Breast cancer (BC) is a disease characterized by the presence of uncontrolled cell growth in the ducts (ductal carcinoma) or lobules (lobular carcinoma) of the mammary gland, and the tumor can invade the surrounding tissues of the breast in later stages. Most breast tumors are invasive or infiltrating, and they are classified by the American Joint Committee on Cancer (AJCC) by several defined stages \[[@CIT0001]\]. Breast cancer is one of the most common diseases in developing countries in the world. It is estimated that there are millions of symptomatic women affected by BC and millions more currently asymptomatic who will develop cancer \[[@CIT0002]\]. Incidence rates are variable in different ethnic groups with 122.6 per 100,000 cases in white women, 118 per 100,000 cases among blacks, 92.8 per 1000,000 cases in Hispanics, 87.9 per 100,000 cases in Asian/Pacific Islanders, and 65.6 per 100,000 in American Indian/Alaskan Natives \[[@CIT0003]\]. In many countries around the world, and particularity in Mexico, the incidence of BC has increased within the last 6 years, and it is now one of the main causes of death in reproductive age females. The mortality incidence rate since 2006 has increased, and has surpassed the mortality rate of cervical cancer. The mortality rate in Mexico was 4,854 deaths in 2009 \[[@CIT0004]\] and has been projected to increase to over 16,500 deaths per year by 2020. Only 10% of all cases are detected at stage I. The state of Jalisco has one of the highest mortality rates for BC \[[@CIT0005]\]. Breast cancer is considered to be a multifactorial disease, and BC might result from a combination of abnormal protein interactions and environmental factors \[[@CIT0006]\]. Previous research has implicated a variety of risk factors for BC, including age, early menarche, menopause, oral contraceptive use, cigarette smoking, alcohol consumption, a family history of BC, breast fibrosis, nulliparity, breastfeeding, ethnicity, nutrition and genetics \[[@CIT0007]\]. Elucidating the genetic variants among different ethnic groups could help to explain the progression of cancer, as well as chemotherapy response.

The *CBS* gene, which is located on chromosome 21q22.3, codes for an enzyme that participates in the folate pathway and catalyzes the transsulfuration of homocysteine and serine to cystathionine as a cysteine precursor \[[@CIT0008]\]. CBS deficiency can modify the stability of a domain or residue in the hydrophobic core, which leads to degradation of the CBS protein. This produces elevated levels in the plasma of homocysteine and methionine, which consequently alter methylation processes \[[@CIT0008]\]. Therefore, a CBS deficiency may have a potential impact on oncogenesis ([Figure 1](#F0001){ref-type="fig"}) \[[@CIT0009]\].

![Schematic representation of *CBS* gene locus on 21 chromosome, indicating position of T833C (intron 7) and 844ins68 (exon 8) polymorphisms](AMS-10-24195-g001){#F0001}

The *CBS* gene has a large number of reported mutations and polymorphisms \[[@CIT0008]\]. The 844ins68 polymorphism at position 844 in the *CBS* gene generates an alternative splicing site that disrupts the protein, which decreases the functional activity of CBS. This polymorphism was initially described in a homocystinuric patient \[[@CIT0010]\]. The 844ins68 polymorphism segregates in *cis* with the T833C mutation \[[@CIT0011]\]. Different studies have found variability in the allelic frequency among ethnic groups, and homozygosity for the 68-bp insertion is rare in population studied \[[@CIT0012]\]. Different populations have also shown variability in the frequency of the heterozygous genotype, with the highest prevalence of 66 at 20% being described in sub-Saharan African \[[@CIT0013]\] and British populations \[[@CIT0014]\]. The median prevalence of 17 at 11% was found in Brazil \[[@CIT0009]\], Holland \[[@CIT0015]\], Italy \[[@CIT0016]\], Spain \[[@CIT0017]\], Ethiopia \[[@CIT0013]\], and the United States \[[@CIT0011]\]. A low prevalence of the heterozygous genotype of 10 at 1% was observed in India \[[@CIT0018]\], Czechoslovakia \[[@CIT0019]\], South Iran \[[@CIT0020]\], China \[[@CIT0021]\], Colombia \[[@CIT0022]\], and Chile \[[@CIT0023]\]. The 844ins68 allele was not observed in Japan or Indonesia \[[@CIT0013]\].

Although the biological impact of the 844ins68 polymorphism in the *CBS* gene is not clear, it has been associated with different pathologies, including cardiovascular defects, neural tube defects, and cancer \[[@CIT0009], [@CIT0012], [@CIT0016], [@CIT0017], [@CIT0021], [@CIT0022], [@CIT0024], [@CIT0025]\]. However, several of these studies that examined the connection between the 844ins68 polymorphism and BC did not reveal any statistically significant associations \[[@CIT0026], [@CIT0027]\].

The aim of this study was to determine the association between the 844ins68 polymorphism in the *CBS* gene and Mexican women with BC.

Material and methods {#S0002}
====================

DNA was extracted from peripheral blood lymphocytes using standard protocols \[[@CIT0028]\]. Blood samples were collected from 371 healthy women recruited as volunteer blood donors with an average age of 32.36 years. These volunteers were not matched by age with the patient group. Blood samples were also collected from 323 patients with clinical and histological confirmation of BC, and all of the patients were residents of the metropolitan area of Guadalajara. The patients were recruited from June 2010 to April 2012. All of the samples were obtained with the appropriate written informed consent and approval from the ethical committee 1305, Centro de Investigación Biomédica de Occidente, IMSS. Efforts were taken to ensure that siblings of those already sampled were excluded. Clinical and demographical data were obtained using written questionnaires. All of the patients were also interviewed to determine occupational exposure and the use of therapeutics.

Genotyping {#S20003}
----------

The amplification of exon 8 in the *CBS* gene was performed by PCR using the following primers: 5'-CTGGCCTTGAGCCCTGAA-3' derived from intron 7 and 5′-GGCCGGGCTCTGGACTC-3' derived from intron 8 \[[@CIT0011]\]. The PCR reactions were performed in a total volume of 15 µl containing 0.2 mM dNTPs (Invitrogen, Carlsbad, CA USA), 5 pmol of primers, 3.0 mM MgCl~2~, 2.5 U Taq polymerase (Invitrogen, Carlsbad, CA USA), and 0.8% bovine serum albumin (Promega, Madison, WI USA). The PCR conditions were 95°C (4 min) followed by 30 cycles of 95°C (1 min), 60°C (1 min), 72°C (2 min) and a final extension at 72°C (7 min). Using this procedure, we obtained fragments of 252 and 184 base pairs (bp). For 844ins68 allele discrimination, the amplified products were separated on 6% polyacrylamide gels (29: 1) followed by silver staining \[[@CIT0029]\]. We determined that the 184-bp fragment represented a wild-type genotype (W). Two fragments at 252 and 184-bp indicated a heterozygous genotype (W/Ins), and one fragment at 252-bp represented the genotype insertion of 68 bp (Ins/Ins).

To determine whether the individuals with the W/Ins and Ins/Ins 844ins68 polymorphism genotypes carried the T833C mutation in the same allele, 2 µl of the PCR products from intron 7 and exon 8 were subjected to restriction enzyme analysis with *Bsr*I (New England Biolabs, Beverly, MA, USA) according to the manufacturer\'s instructions, at 65°C for 12 h. After electrophoresis on an 8% polyacrylamide gel (19: 1), the product was visualized by silver staining \[[@CIT0029]\], which revealed the presence of allele 833C with 209- and 184-bp fragments \[[@CIT0011]\].

Statistical analysis {#S20004}
--------------------

Allele frequencies were obtained by direct counting. The Hardy-Weinberg equilibrium was tested by a goodness-of-fit χ^2^ test to compare the observed genotype frequencies to the expected frequencies among control subjects. Odds ratios and 95% confidence intervals (CI) were also calculated. A two-sided *p* \< 0.05 was considered to be statistically significant. All statistical analyses were performed using PASW Statistic Base 18 software, 2009 (Chicago, IL).

Results {#S0005}
=======

Demographic characteristic of study groups {#S20006}
------------------------------------------

[Table I](#T0001){ref-type="table"} shows the comparative epidemiological data from the BC patients and the control individuals. In the patient group, the observed average age was 53.75 years, ranging from 28 to 88 years of age. Menarche had a mean age of 12.62 years in patients and 12.17 years in controls. Body mass index (BMI) ≥ 30--34.9 kg/m^2^ (crude OR = 30.0, 95% CI: 10.9--83.5, *p* \< 0.0001) and ≥ 35 kg/m^2^ -- \> 40 kg/m^2^ (OR = 12, 95% CI: 5.0--32.5, *p* \< 0.0001), oral contraceptive use (OR = 2.5, 95% CI: 1.8--3.5, *p* \< 0.0001), breastfeeding (OR = 2.7, 95% CI: 2.0--3.7, *p* \< 0.0001), menopause (OR = 23.2, 95% CI: 15.1--35.8, *p* \< 0.0001), familial history (FH) (OR = 2.9, 95% CI: 2.1--3.9, *p* \< 0.0001) and maternal familial history (OR = 2.6, 95% CI: 1.8--3.6, *p* \< 0.0001) were presented as risk factors.

###### 

Demographic data of the study groups

  Parameter                                                              Breast cancer patients   Controls   OR (95% CI)   Value of *p*                       
  ---------------------------------------------------------------------- ------------------------ ---------- ------------- -------------- ------------------- ----------------------------------------------
  Age \[years\]                                                                                                                                               
   Mean (SD)                                                             (53.75)                  11.17      (32.36)       9.57                               \< 0.0001^[1](#TF0001){ref-type="table-fn"}^
  Menarche \[years\]                                                                                                                                          
   Mean (SD)                                                             (12.62)                  1.6        (12.17)       1.07                               \< 0.0001^[1](#TF0001){ref-type="table-fn"}^
    7--10                                                                \(20\)                   6          \(6\)         2              3.8 (1.5--9.7)      0.002
    11--13                                                               \(213\)                  66         \(324\)       87             0.28 (0.19--0.41)   \< 0.0001
    14--18                                                               \(90\)                   28         \(41\)        11             2.65 (1.7--3.9)     \< 0.0001
  Body mass index (BMI)[\*](#TF0002){ref-type="table-fn"} \[kg/m^2^\]:                                                                                        
   18.5--24.9 (normal)                                                   \(84\)                   26         \(202\)       55             0.29 (0.21--0.40)   \< 0.0001
   ≥ 25--29.9 (overweight)                                               \(111\)                  34         \(160\)       43             0.69 (0.50--0.93)   0.018
   ≥ 30--34.9 (obesity I)                                                \(80\)                   25         \(4\)         1              30 (10.9--83.5)     \< 0.0001
   ≥ 35 -- \> 40 (obesity II--III)                                       \(48\)                   15         \(5\)         1              12 (5.0--32.5)      \< 0.0001
  Oral contraceptive use:                                                                                                                                     
   Yes                                                                   \(147\)                  46         \(91\)        25             2.5 (1.8--3.5)      \< 0.0001
   No                                                                    \(176\)                  54         \(280\)       75                                 
  Breastfeeding:                                                                                                                                              
   Yes                                                                   \(215\)                  66         \(155\)       42             2.7 (2.0--3.7)      \< 0.0001
   No                                                                    \(108\)                  34         \(216\)       58                                 
  Menopause:                                                                                                                                                  
   Postmenopausal                                                        \(222\)                  69         \(32\)        9              23.2 (15.1--35.8)   \< 0.0001
   Premenopausal                                                         \(101\)                  31         \(339\)       91                                 
  Tobacco consumption:                                                                                                                                        
   Yes                                                                   \(80\)                   25         \(80\)        22                                 0.317
   No                                                                    \(243\)                  75         \(291\)       78                                 
  Alcohol consumption:                                                                                                                                        
   Yes                                                                   \(64\)                   20         \(95\)        26                                 0.07
   No                                                                    \(259\)                  80         \(276\)       74                                 
  Familial history (FH)[\*\*](#TF0003){ref-type="table-fn"}:                                                                                                  
   Yes                                                                   \(198\)                  61         \(132\)       36             2.9 (2.1--3.9)      \< 0.0001
   No                                                                    \(125\)                  39         \(239\)       64                                 
  Cancer type of FH:                                                                                                                                          
   No                                                                    \(125\)                  39         \(239\)       64             0.3 (0.25--0.47)    \< 0.0001
   Breast cancer                                                         \(41\)                   13         \(16\)        4              3.2 (1.7--5.8)      \< 0.0001
   Cancer + breast cancer                                                \(30\)                   9          \(30\)        8                                  0.57
   Diabetes mellitus (DM)                                                \(27\)                   8          \(56\)        15             0.51 (0.31--0.83)   0.006
   Arterial hypertension (AH)                                            \(6\)                    2          \(29\)        8              0.22 (0.09--0.54)   0.0003
   DM-AH                                                                 \(21\)                   7          \(0\)         0              8.1 (1.0--66.9)     0.019
   DM-AH-cancer                                                          \(73\)                   22         \(1\)         1              108 (14.9--782)     \< 0.0001
  Inheritance:                                                                                                                                                
   No                                                                    \(125\)                  39         \(239\)       65             0.3 (0.25--0.47)    \< 0.0001
   Maternal                                                              \(125\)                  39         \(72\)        19             2.6 (1.8--3.6)      \< 0.0001
   Paternal                                                              \(33\)                   10         \(36\)        10                                 0.82
   Both                                                                  \(40\)                   12         \(24\)        6              2.0 (1.2--3.4)      0.007

Fisher\'s exact test. SD, standard deviation.

According to OMS classifications (Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Ginebra (Suiza): Organización Mundial de la Salud, 2004).

Positive familial history of cancer and leukemia in first and second degree relatives of patients.

Clinicopathological characteristics of BC patients {#S20007}
--------------------------------------------------

[Table II](#T0002){ref-type="table"} shows the general clinical characteristics of the patient group. We observed that 26% of the patients had breast fibrosis and arterial hypertension (AH), approximately 40% were positive for hormonal receptors, 89% had ductal histology, and 62% had stage III--IV tumors. Approximately 20% of the patients had high levels of serum glutamate oxaloacetate transaminase (SGOT), alkaline phosphatase (ALP), GGT and glucose.

###### 

Clinical data of patients with breast cancer

  Parameter                                                     Breast cancer   
  ------------------------------------------------------------- --------------- ----
  Personal medical history:                                                     
   No                                                           173             53
   DM-AH                                                        83              26
   Breast fibrosis-AH                                           21              7
   Hysterectomy, AH                                             28              9
   Depression, pregnancy, preeclampsia                          5               1
   Thrombosis                                                   7               2
   Hyperthyroidism                                              6               2
  Tumor localization:                                                           
   Right/left                                                   311             96
   Bilateral                                                    12              4
  BI-RADS                                                                       
   Grade IV                                                     239             75
   Grade V                                                      84              26
  Diagnostic time \[years\]:                                                    
   1--4                                                         215             67
   5--9                                                         100             31
   10--15                                                       8               2
  Tumor markers:                                                                
   Luminal A                                                    140             43
   Luminal B                                                    86              27
   Triple negative                                              53              16
   Her 2-neu                                                    44              14
  Histology:                                                                    
   Ductal                                                       288             89
   Lobular                                                      28              9
   Mixed                                                        7               2
  Tumor stage:                                                                  
   I--II                                                        122             38
   III--IV                                                      201             62
  Lymph node status:                                                            
   Yes                                                          241             75
   No                                                           82              25
  Metastasis:                                                                   
   Yes                                                          95              29
   No                                                           228             71
  Metastasis site (*n* = 95)                                                    
   Lung                                                         7               7
   Bone                                                         47              49
   Liver                                                        3               3
   Bone-lung-liver                                              36              39
   Lung-central nervous system                                  2               2
  Chemotherapy response:                                                        
   Yes                                                          223             69
   No                                                           100             31
  Chemotherapy type:                                                            
   FEC                                                          264             82
   Other                                                        45              14
   No chemotherapy                                              14              4
  Chemotherapy toxicity:                                                        
   Yes                                                          255             79
   No                                                           68              21
  Laboratory test:                                                              
   Hemoglobin \[g/dl\]:                                                         
    \< 11                                                       27              8
    11--16.4                                                    296             92
   Hematocrit (%):                                                              
    \< 37                                                       58              18
    37--47                                                      265             82
   Platelets \[mm^3^\]:                                                         
    \< 450,000                                                  20              6
    150,000--450,000                                            208             64
    \> 450,000                                                  95              30
   Leukocytes \[mm^3^\]:                                                        
    \< 150,000                                                  35              11
    150,000--500,000                                            288             89
   Urea \[mg/dl\]:                                                              
    \> 20                                                       44              14
    6--20                                                       279             86
   Creatine \[mg/dl\]:                                                          
    \> 1.1                                                      17              5
    3--1.1                                                      306             95
   Serum glutamate-oxaloacetate transaminase (SGOT) \[mI/l\]:                   
    \> 35                                                       68              21
    0--35                                                       255             79
   Serum glutamic pyruvic transaminase (SGPT) \[µI/l\]:                         
    \> 45                                                       53              16
    5--45                                                       270             84
   Lactate dehydrogenase (LDH) \[µI/l\]:                                        
    \> 333                                                      60              19
    105--333                                                    263             81
   Alkaline phosphatase (ALP) \[µI/l\]:                                         
    \> 45                                                       69              21
    5--45                                                       254             79
   γ-Glutamyltransferase (GGT) \[µI/l\]:                                        
    \> 45                                                       70              22
    5--45                                                       253             78
   Glucose \[µI/l\]                                                             
    74--106                                                     65              20
    \> 106                                                      258             80

FEC -- 5-fluorouracil, epirubicin, cyclophosphamide, others -- paclitaxel, docetaxel, trastuzumab.

[Table III](#T0003){ref-type="table"} summarizes the multivariate logistic regression analysis, where the BC group was classified as tumor stage I--II and III--IV as the dependent variables. The presence of menarche at 7--10 years (adjusted OR = 5.4, 95% CI: 1.05--28.1, *p* = 0.044), tobacco consumption (OR = 2.5, 95% CI: 1.1--5.7, *p* = 0.024), chemotherapy (FEC, 5-fluorouracil-epirubicin-cyclophosphamide) (OR = 2.7, 95% CI: 1.1--6.6, *p* = 0.025) and nodule metastatic (OR = 2.8, 95% CI: 1.3--6.1, *p* = 0.006) were risk factors. In contrast, not using oral contraceptives (OR = 0.47, 95% CI: 0.24--0.92, *p* = 0.027) and the absence of a familial history of cancer (OR = 0.24, 95% CI: 0.07--0.78, *p* = 0.018) were protection factors.

###### 

The regression binary logistic of the breast cancer group

                                   B         SD      Wald    d*f*   Value of *p*   OR      95% CI   
  -------------------------------- --------- ------- ------- ------ -------------- ------- -------- --------
  **Menarche (7--10 years)**       1.692     0.839   4.068   1      0.044          5.430   1.049    28.114
  **No oral contraceptive use**    --0.743   0.337   4.864   1      0.027          0.476   0.246    0.921
  **Tobacco (consumption)**        0.937     0.415   5.096   1      0.024          2.552   1.131    5.756
  **Familial history (absence)**   --1.407   0.595   5.582   1      0.018          0.245   0.076    0.787
  **Chemotherapy (FEC)**           1.009     0.450   5.023   1      0.025          2.743   1.135    6.627
  **Lymph node status**            1.054     0.386   7.461   1      0.006          2.869   1.347    6.112
  **Constant**                     67.03     70843   0.000   1      0.999          1.293            

Variables included in the analysis: dependent: breast cancer patients classified by tumor status as I--II and III--IV. Independent: personal medical history, menarche ranges 7--10 years, 11--13 years, 14--18 years; menopause, pregnancies, breastfeeding, oral contraceptive use, tobacco and alcohol consumption, HF, HF type: breast cancer, DM, AH, DM-AH-cancer, parental inheritance: mother, father, both, and BMI: 18.5--24.9, ≥ 25--29.9, ≥ 30--34.9, ≥ 35--\> 40 kg/m^2^, years of diagnosis; BI-RADS, histology, tumor markers, lymph node status, metastasis, MTS tissue, response to chemotherapy, type of chemotherapy, toxicity in chemotherapy, laboratory tests (HB, HTO, platelets, leukocytes, urea, creatinine, SGOT, SGPT, LDH, ALP, GGT and glucose).

Frequency of 844ins68 polymorphism of *CBS* gene between study groups {#S20008}
---------------------------------------------------------------------

Co-segregation of the 844ins68 and T833C polymorphisms were observed in the controls and patient groups. For that reason, we just present the 844ins68 polymorphism data in [Table IV](#T0004){ref-type="table"}. The W/W genotype was observed in 72% (233/323) of patients compared with 86% (320/371) of the controls (OR = 0.41, 95% CI: 0.28--0.60, *p* = 0.001). The heterozygous genotype (W/Ins) was observed in 26% of the patients (83/323) and 13% (49/371) of the controls (OR = 2.2, 95% CI: 1.5--3.3, *p* = 0.0001). The polymorphic genotype (Ins/Ins) was observed in 2% (7/323) of the controls and in 1% (2/371) of the patients (*p* = 0.05). All of the genotype distributions were in Hardy-Weinberg equilibrium. All of the samples were analyzed, and all of the genotypes (373 controls and 232 BC patients) were obtained. In addition, no differences were found with regard to the general characteristics of the study groups and 844ins68/ T833C *CBS* polymorphisms, except that the absence of metastatic lymph was associated with the genotype W/W (OR = 0.430, 95% CI: 0.21--0.85, *p* = 0.015) as a protective factor.

###### 

Genotype and allelic distribution of the 844ins68/T833C CBS polymorphism[\*\*](#TF0005){ref-type="table-fn"} in healthy controls and breast cancer patients

  Genotypes               Groups                                           
  ----------------------- -------- ------ ----- ------ ------ ------------ --------
  *W/W*                   233      72     320   86     0.41   0.28--0.60   0.001
  *W/Ins*                 83       26     49    13     2.2    1.5--3.3     0.0001
  *Ins/Ins*               7        2      2     1      4.0    0.84--19.8   0.05
  *W/Ins* and *Ins/Ins*   90       28     51    14     2.4    1.6--3.5     0.0001
  Alleles:                                                                 
  * W*                    549      0.85   689   0.93   0.43   0.30--0.61   0.0001
  * Ins*                  97       0.15   53    0.07   2.2    1.6--3.2     0.0001

Hardy-Weinberg equilibrium in the controls (X^2^ = 0.015; p = 0.90)

Marker informativity 0.87 was assessed within a range of 0--1: markers with a score greater than 0.7 were considered to be highly informative, whereas markers with a value of 0.44 were considered to be moderately informative \[[@CIT0006]\].

Comparison between heterozygous genotype patients with clinical-pathologic characteristics of BC patients {#S20009}
---------------------------------------------------------------------------------------------------------

[Table V](#T0005){ref-type="table"} shows that the patients with the heterozygous genotype were associated with more than one variable listed in [Tables I](#T0001){ref-type="table"} and [II](#T0002){ref-type="table"}. The heterozygous patients who had undergone menopause were associated with menarche (7--10 years) (OR = 10.85, 95% CI: 1.07--109.8, *p* = 0.040) and elevated levels of the enzyme GGT (OR = 2.17, 95% CI: 1.1--4.26, *p* = 0.02) as risk factors.

###### 

Association of the 844ins68/T833C CBS polymorphism with more than one variable of the general characteristics of the breast cancer patients

  Variable                Polymorphism    Menarche (7--10 years)     Value of *p*                           
  ----------------------- --------------- -------------------------- -------------- ------- --------------- -------
  Menopause               W/Ins-Ins/Ins   3                          21             10.85   (1.07--109.8)   0.040
  W/W                     1               76                                                                
                                          **GGT levels**                                                    
  **High**                **Normal**                                                                        
                          W/Ins-Ins/Ins   20                         46             2.17    (1.1--4.26)     0.02
  W/W                     26              130                                                               
                                          **Alcohol consumption**                                           
  **Tumor stage**                         **Yes**                    **No**                                 
  I--II                   W/Ins-Ins/Ins   9                          18             3.1     (1.17--8.49)    0.019
  W/W                     13              82                                                                
                                          **Diagnostic \[years\]**                                          
  Chemotherapy response   **5--9**        **1--4**                                                          
                          W/Ins-Ins/Ins   24                         39             1.97    (1.05--3.69)    0.031
  W/W                     38              122                                                               
                                          **LDH serum levels**                                              
  **High**                **Normal**                                                                        
                          W/Ins-Ins/Ins   17                         46             2.2     (1.08--4.47)    0.027
  W/W                     23              137                                                               
                                          **GGT levels**                                                    
  **High**                **Normal**                                                                        
                          W/Ins-Ins/Ins   21                         42             2.46    (1.2--4.8)      0.007
                          W/W             27                         133                                    
                                          **Diagnosis \[years\]**                                           
  **BMI**                                 **5--9**                   **1--4**                               
  ≥ 30 -- \> 40           W/Ins-Ins/Ins   26                         34             2.07    (1.1--3.86)     0.021
                          W/W             41                         111                                    
                                          **Tumor stage**                                                   
  **III--IV**             **I--II**                                                                         
                          W/Ins-Ins/Ins   23                         7              3.2     (1.2--8.3)      0.013
                          W/W             41                         40                                     

The heterozygous patients with stage I--II tumors were associated with alcohol consumption (OR = 3.1, 95% CI: 1.17--8.49, *p* = 0.019). The heterozygous patients who responded to chemotherapy showed an association with the following: 1) the diagnosis of 5--9 years (OR = 1.97, 95% CI: 1.05--3.69, *p* = 0.031), high levels of LDH (OR = 2.2, 95% CI: 1.08--4.47, *p* = 0.027), and high levels of GGT (OR = 2.4, 95% CI: 1.2--4.8, *p* = 0.007). Heterozygous patients with a BMI of 18.5--30 kg/m^2^ and ≥ 30 kg/m^2^ -- \> 40 kg/m^2^ were associated with the diagnosis of 5--9 years (OR = 2.07, 95% CI: 1.1--3.86, *p* = 0.021), and tumor stage III--IV (OR = 3.2, 95% CI: 1.2--8.3, *p* = 0.013).

Discussion {#S0010}
==========

In Mexico, BC is considered to be a major health population issue because it is currently one of the leading causes of death in productive age women \[[@CIT0004], [@CIT0005]\]. These facts are consistent with our observations in the current study, wherein the average age was 53.75 ±11.17, early menarche (7--10 years), BMI obesity II--III (≥ 30 kg/m^2^ to \> 40 kg/m^2^), menopause status, familial history of cancer, diabetes mellitus (DM) and hypertension were observed as risk factors. These observations have been observed in other reports \[[@CIT0030]--[@CIT0036]\]. Breastfeeding was recorded in 66% of the patients in contrast with 42% of the controls, which made it a risk factor. However, these results should be taken with caution, because they did not consider the period of lactation. It is hypothesized that prolonged breastfeeding reduces the risk of BC, and that risk is reduced by 4% for each 12 months of breastfeeding \[[@CIT0037]\]. One study estimated that approximately 3% of breast cancers in UK women were associated with breastfeeding for less than 6 months \[[@CIT0038]\].

When the BC group was stratified by tumor stage, as either I--II or III--IV, and compared with the clinical and biochemical characteristics of BC, early menarche (7--10 years), contraceptive hormonal use, familial history, tobacco consumption, metastasis to lymph nodes, and chemotherapy type (FEC) emerged as risk factors. The association of tobacco use with BC is still controversial, and one study showed that smokers had a BC risk of 10--20% compared to nonsmokers \[[@CIT0038]--[@CIT0040]\]. This association depends on the number of cigarettes smoked per day and exposure time; however, in most studies, these parameters are not considered. In this regard, in our study, patients with stage III--IV tumors who smoked had increased risk, and our data are consistent with previous reports \[[@CIT0039], [@CIT0040]\]. Also, the presence of lymph node metastases and chemotherapy type were risk factors for BC patients with stage III--IV tumors. In fact, the BC tumor stage is important for determining treatment, and a predictor of survival. There is evidence that patients with micrometastases in axillary lymph nodes have an increased risk of distant metastases compared to patients without axillary lymph node metastases \[[@CIT0039]\].

Among factors that can favor carcinogenesis are individual genetic variations for susceptibility. Polymorphisms, which are low penetrance genes, are risk factors in cancer \[[@CIT0040]--[@CIT0044]\]. Folate metabolism has been proposed to be a contributing factor, by promoting DNA hypomethylation of key regulatory genes and uracil misincorporation into DNA, which leads to double-strand breaks and chromosomal aberrations \[[@CIT0045]\]. The biochemical effect of the 844ins68 polymorphism has been associated with either low levels of homocysteine and methionine \[[@CIT0046], [@CIT0047]\], or high levels of homocysteine \[[@CIT0048]\] when it co-segregates in *cis* with T833C \[[@CIT0046]--[@CIT0049]\]. Our findings are consistent with co-segregation because we observe similar frequencies of both the 844ins68 and the T833C polymorphisms. In the literature, several population frequencies of 844ins68 have been published \[[@CIT0012]--[@CIT0025]\]. Little is known about the association of this polymorphism with BC in our population; the allelic frequency of this polymorphism was 0.07 in controls and 0.15 in BC patients and was associated as a risk factor. However, a study observed the association between 844ins68 polymorphism with lower survival in neck cancer \[[@CIT0049]\].

A possible explanation could be that CBS enzyme catalyzes the condensation of homocysteine with serine to give rise to cystathionine as a precursor of cysteine. The CBS deficiency can alter the stability of a domain or residue in the hydrophobic core, which leads to degradation of the protein and produces elevated plasma homocysteine and methionine leading to genomic DNA hypomethylation \[[@CIT0050]\]. This may potentially have an impact on BC oncogenesis.

Although the sample representing the association of the W/Ins-Ins/Ins genotype, as a risk factor in postmenopausal patients presenting early menarche, was small, this association was observed in this study, and probably both prolonged exposure to estrogens and nutritional status could be the explanation; however, there is no evidence in the literature of this association. Another possible explanation is that given folates are involved in DNA methylation \[[@CIT0009], [@CIT0044]\], variations in genes of this pathway, such as the *CBS* gene, may cause poor metabolism of folate and may alter DNA methylation patterns and influence the expression, integrity and stability of DNA \[[@CIT0009]\]. Moreover, alteration in the levels of folate may have an effect on other metabolic pathways, such as the estrogen pathway. Zhu *et al*. postulated that a folate and methionine deficiency may be associated with BC because of methylation of the estrogen receptor gene\'s CpG islands \[[@CIT0051]\]; this finding is related to the lack of gene expression in breast tumors that are positive for the estrogen receptor.

We also observed the association of the W/Ins-Ins/Ins genotype in postmenopausal patients with elevated levels of GGT as a risk factor. This observation could possibly be explained by the participation of GGT in cellular glutathione metabolism, modulated redox reactions and its reconstitution of cellular antioxidant, antitoxic defense, cell proliferation, apoptosis, tumor progression, invasion and cancer cell drug resistance. The expression of GGT is often increased in tumors and has been suggested to be a biomarker \[[@CIT0052]--[@CIT0054]\]. The GGT enzyme is expressed constitutively in various organs and rises significantly in premalignant lesions or malignant tumors; therefore, it is considered to confer a favorable environment for the growth and survival of neoplastic cells \[[@CIT0052]\]. This study provides new data for alcohol consumption as a risk factor, because of the observed association between the W/Ins-Ins/Ins *CBS* genotype in BC with tumor stage I--II and alcohol consumption. It is known that alcohol increases the endogenous levels of estrogen, which is a known risk factor for BC \[[@CIT0055]\].

The response to chemotherapy in BC patients with evolution from 5 to 9 years and elevation of LDH and GGT enzymes were influenced by the W/Ins-Ins/Ins *CBS* genotype in this study; but it is well known that the response to chemotherapy depends on several factors. Adjuvant chemotherapy can induce persistent resistance to the drugs with longer exposure, and the anthracyclines have achieved longer time to progression and survival time compared with cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy \[[@CIT0056]\].

In contrast, it has been observed that high expression of LDH and GGT is indicative of a poor response in patients with BC at later stages. The elevated expression of these enzymes is thought to reflect tumor aggressiveness \[[@CIT0057]\]. Another factor that may influence the response to chemotherapy is menopause, which is associated with a less favorable response \[[@CIT0058]\]. However, there are no studies concerning the influence of the W/Ins-Ins/Ins CBS genotype and the response to chemotherapy depending on the overexpression of the LDH and GGT enzymes.

The W/Ins-Ins/Ins genotype is a risk factor in BC patients with a BMI ≥ 29.9 kg/m^2^ -- \> 40 kg/m^2^ who were diagnosed in 5 to 9 years, have advanced tumor stage (III--IV) and have an inherited family history. Obesity is a major risk factor for developing BC in postmenopausal women. Weight gain in women with postmenopausal BC in industrialized countries has a significant impact on health \[[@CIT0059]\]. Several studies have reported that women who are obese at diagnosis have an increased risk of lymph node metastasis \[[@CIT0060]\]. In fact, there are several theories that attempt to explain this association, involving the role of leptin, insulin and other molecules that mediate the inflammatory process independently of estrogen. In addition, peripheral circulating estrogens are elevated in obese postmenopausal women. Another current hypothesis proposes that obesity is associated with metabolic syndrome, which activates molecular processes that are mitogenic in breast epithelial cells and stimulate neoplasia. A third proposal suggests that adipocytes and their autocrine mechanisms are important for BC development \[[@CIT0032]\].

Several hypotheses have been proposed to try to explain this association, which influences growth and BC prognosis. It has been suggested that adipocytes are now recognized as active endocrine cells that produce hormones, growth factors and cytokines. In fact, the most likely scenario is that all of these mechanisms may combine to explain the relationship linking menopause and subsequent weight gain in BC \[[@CIT0060]--[@CIT0062]\].

In conclusion, the 844ins68/T833C CBS polymorphism contribute significantly to BC susceptibility in: 1) menopause and high GGT levels, 2) chemotherapy type and high LDH levels, 3) chemotherapy type and high GGT levels, and 4) BMI and III--IV tumor stage, in the analyzed sample from the Mexican population, but further studies are required to confirm or reject these observations.
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